TCT-465 Drug-Eluting Balloon in the Treatment of Instent Restenosis and Diffuse Coronary Artery Disease; Real World Experience from a Single Center Registry

  • Basavarajaiah S
  • Latib A
  • Hasegawa T
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: Drug-eluting balloons (DEB) are emerging as an alternative treatment for coronary stenoses when scaffolding is undesirable. We report a real world, single center experience of DEB usage over a 19-month period in the treatment of in-stent restenosis (ISR) and de novo coronary artery disease. Methods: Consecutive patients treated with the In.Pact FalconTM (Medtronic Inc., Minneapolis, MN, USA) paclitaxel eluting balloon as part of a coronary revascularization strategy between May 2009 and December 2010 were retrospectively studied. The primary outcome was a composite of all-cause death, myocardial infarction (MI) and target vessel revascularization (TVR) at a minimum of 6 months follow-up. Secondary outcomes were in-segment restenosis and the individual components of the primary composite. Results: A total of 122 lesions were successfully treated in 75 patients. The mean age was 66.6+/-9.3 years and 89.3% were male. The majority of patients (85.3%) had stable angina, and 62.7% had triple vessel CAD. The predominant indication for DEB use was ISR (62.7%), with diffuse disease (34.7%) and focal, small vessel disease (2.6%) accounting for the remainder. 77.3% of lesions were classified as ACC/AHA B2 or C, and 20.0% involved a bifurcation. A mean of 1.5+/-0.8 DEB were used per patient. Bailout stenting was required in 25.8% of lesions, 19.3% for angiographic optimization and 6.5% for dissection caused by balloon injury. The median clinical follow-up was 13 months (IQR 6-16 months). The primary composite endpoint occurred in 13.3% of patients, with the individual components of death, MI and TVR occurring in 0%, 2.7% and 12.0% respectively. Of the 78 lesions (63.9%) followed up angiographically at a median of 8 months (IQR 5-18 months), target lesion revascularization (TLR) occurred in 13.9%, and restenosis in 30.8%; 41.7% was focal and 37.5% was diffuse in character. Restenosis was significantly more common when DEB were used for drug-eluting stent ISR (DES-ISR) than for bare metal stent ISR (BMS-ISR) or de novo disease (47.5.% vs. 0% vs. 16.1%; p=0.003). Conclusion: DEB can be used safely to treat ISR and diffuse, small vessel CAD. However, their use in DES-ISR is associated with significantly higher rates of recurrent restenosis at 8 months than their use in BMS-ISR or de novo disease.

Cite

CITATION STYLE

APA

Basavarajaiah, S., Latib, A., Hasegawa, T., Sticchi, A., Bertoldi, L., Naganuma, T., … Colombo, A. (2013). TCT-465 Drug-Eluting Balloon in the Treatment of Instent Restenosis and Diffuse Coronary Artery Disease; Real World Experience from a Single Center Registry. Journal of the American College of Cardiology, 62(18), B142. https://doi.org/10.1016/j.jacc.2013.08.1208

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free